Related Experiment Video
Updated: Apr 16, 2026

Author Spotlight: Utilizing Next-Generation Polymerized Human Hemoglobin for Improved Donor Lung Evaluation and Preservation in Rats
Published on: June 14, 2024
Bicarbonate- versus lactate-buffered solutions for acute continuous haemodiafiltration or haemofiltration
Jin Hui Tian1, Bin Ma, KeHu Yang
1Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, No. 199, Donggang West Road, Lanzhou City, Gansu, China, 730000.
Bicarbonate-buffered solutions in continuous renal replacement therapy for acute kidney injury (AKI) may reduce cardiovascular events and lower lactate levels. However, no significant differences were found in mortality or other key markers compared to lactate-buffered solutions.
Area of Science:
- Nephrology and Critical Care Medicine
- Renal Replacement Therapy
- Acid-Base Physiology
Background:
- Acute kidney injury (AKI) impairs kidney function, necessitating renal replacement therapies like continuous haemodiafiltration (HDF) and haemofiltration (HF).
- The choice of buffered dialysates (bicarbonate vs. lactate) in HDF/HF impacts acid-base balance and electrolytes, but their comparative benefits and harms in AKI patients are not well-established.
Purpose of the Study:
- To evaluate the benefits and harms of bicarbonate-buffered versus lactate-buffered solutions for HDF or HF in patients with AKI.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) and quasi-RCTs comparing bicarbonate-buffered and lactate-buffered solutions for AKI.
- Searched Cochrane Renal Group's Specialised Register and Chinese Biomedical Literature Database up to January 6, 2015.
- Independent assessment of study eligibility, quality (Cochrane risk of bias tool), and data extraction; results reported as risk ratios (RR) or mean differences (MD) with 95% confidence intervals (CI).
Main Results:
- Four studies with 171 patients were included; overall study quality was suboptimal with reporting omissions.
- Bicarbonate-buffered solutions were associated with significantly lower serum lactate levels (MD -1.09 mmol/L).
- No significant differences were observed in mortality, serum creatinine, pH, or other key electrolytes. One study suggested fewer cardiovascular events and less hypotension with bicarbonate solutions.
Conclusions:
- Bicarbonate-buffered solutions may offer benefits such as reduced cardiovascular events and lower serum lactate in AKI patients undergoing HDF/HF.
- No significant differences were found for mortality, serum creatinine, or acid-base parameters.
- Primary outcomes like ICU stay, hospital stay duration, and relapse could not be adequately assessed due to study limitations.
More Related Videos
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
08:07Author Spotlight: Isolation and Characterization of Equine Submucosal Enteric Glia — Implications for Preventing Postoperative Complications in Colic Surgery
Published on: October 4, 2024
Related Concept Videos
Bicarbonate-Carbonic Acid Buffer
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Continuous Renal Replacement Therapy
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Hemodialysis II: Procedure and Complications